SPRB

Business Context and Reporting Period

Company: Spruce Biosciences, Inc. (SPRBD)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2025
Business Overview: Spruce is a late-stage biopharmaceutical company focused on developing therapies for neurological disorders. Its primary product candidates include tralesinidase alfa (TA-ERT) for MPS IIIB, tildacerfont for Major Depressive Disorder (MDD) and Congenital Adrenal Hyperplasia (CAH), and SPR202. The company has no approved products and has not generated product revenue.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Collaboration revenue dropped to $0 for the six months ended June 30, 2025, compared to $3.6 million in the prior year period. The company recognized the full transaction price from its Kaken Pharmaceutical agreement in the prior year.
• Operating Expenses: Total operating expenses decreased by approximately $9.1 million year-over-year.
  • R&D Expenses: Decreased by $8.0 million to $10.4 million. This reduction was driven by the discontinuation of the tildacerfont CAH development program, a reduction in recorded liabilities related to the Allievex asset purchase, and a 55% workforce reduction in April 2025.
  • G&A Expenses: Decreased by $1.1 million to $6.8 million, primarily due to lower stock-based compensation expense.
• Liquidity: Cash and cash equivalents declined from $38.8 million at December 31, 2024, to $16.4 million at June 30, 2025, reflecting a net cash burn of $21.6 million from operations.
• Capital Structure: The company effected a 1-for-75 reverse stock split in July 2025 (subsequent to the period end) following delisting from Nasdaq. Stock now trades on OTCQB under symbol SPRBD.

Guidance, Outlook, and Risks

• Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. With $16.4 million in cash, the company believes it is insufficient to fund operations and debt obligations for at least 12 months without additional financing.
• Financing Needs: The company requires substantial additional capital to develop TA-ERT and fund operations. It may seek equity offerings, debt financing, or strategic collaborations, which could result in dilution or restrictive covenants.
• Product Pipeline:
  • TA-ERT: The company intends to submit a Biologics License Application (BLA) for TA-ERT for MPS IIIB in Q1 2026, seeking accelerated approval based on existing clinical data.
  • Tildacerfont: A Phase 2 proof-of-concept study (TAMARIND) for MDD is ongoing, with topline results expected in H1 2026. The CAH program was discontinued.
• Key Risks:
  • Delisting: Failure to regain Nasdaq compliance could adversely affect stock liquidity and price.
  • Regulatory Approval: Clinical trials may fail to demonstrate safety/efficacy, or regulatory approval may be delayed or denied.
  • Third-Party Reliance: The company relies entirely on third parties for manufacturing and clinical trial conduct.

Investor Verification Checklist

• Cash Runway: Verify the timeline for raising additional capital given the "substantial doubt" regarding going concern status and the $16.4 million cash balance.
• Debt Covenants: Review the terms of the Silicon Valley Bank term loan (maturing Jan 1, 2026) and confirm compliance with covenants, noting the loan is secured by substantially all assets excluding IP.
• TA-ERT BLA Submission: Monitor the Q1 2026 timeline for the BLA submission and the initiation of the required confirmatory Phase 3 trial.
• Reverse Stock Split Impact: Assess the impact of the 1-for-75 reverse stock split on share liquidity and the ability to regain Nasdaq listing.
• Allievex Liabilities: Confirm the status of the $1.5 million remaining accrued liability from the Allievex asset purchase and the $2.6 million contingent receivable.